Tofacitinib Inhibits Leukocyte Trafficking Across the Intestinal Endothelial Barrier in a Specific Cohort of Ulcerative Colitis Patients

Inflamm Bowel Dis. 2022 Jun 3;28(6):971-976. doi: 10.1093/ibd/izab349.
No abstract available

Keywords: Ulcerative Colitis; endothelial cells; leukocytes; transcriptomics.

Plain language summary

The JAK/STAT inhibitor tofacitinib, recently approved for the treatment of ulcerative colitis, is found to modulate the intestinal endothelial barrier functions in directing the leukocyte adhesion and transmigration in ulcerative colitis patients displaying high levels of endothelial STAT3/STAT6 phosphorylation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Colitis, Ulcerative* / drug therapy
  • Humans
  • Leukocytes
  • Piperidines / pharmacology
  • Pyrimidines / pharmacology
  • Pyrimidines / therapeutic use

Substances

  • Piperidines
  • Pyrimidines
  • tofacitinib